51
|
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA. Predictors of early polymetastatic relapse following stereotactic ablative radiotherapy for up to 5 oligometastases: a secondary analysis of the phase II SABR-5 trial. Int J Radiat Oncol Biol Phys 2022; 114:856-861. [PMID: 35840110 DOI: 10.1016/j.ijrobp.2022.06.094] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 05/24/2022] [Accepted: 06/26/2022] [Indexed: 10/17/2022]
Abstract
PURPOSE A subset of patients with oligometastatic cancer experience early widespread cancer dissemination and do not benefit from metastasis-directed therapy such as stereotactic ablative radiotherapy (SABR). This study aimed to identify factors associated with early polymetastatic relapse (PMR). METHODS AND MATERIALS The XXX trial was a single arm phase II study conducted at all 6 regional cancer centres across XXX. SABR for oligometastases was only offered on trial. Patients with up to 5 oligometastatic lesions (total, progressing or induced) received SABR to all lesions. Patients were 18 years of age or older, ECOG 0-2 and life expectancy ≥ 6 months. This secondary analysis evaluated factors associated with early PMR, defined as disease recurrence within 6 months of SABR which is not amenable to further local treatment. Univariable and multivariable analyses were performed using binary logistic regression. The Kaplan Meier method and log-rank tests assessed PMR-free survival and differences between risk groups, respectively. RESULTS Between November 2016 and July 2020, 381 patients underwent treatment on XXX. A total of 16% of patients experienced PMR. Worse performance status (ECOG 1-2 vs 0; HR=2.01, p=0.018), non-prostate/breast histology (HR=3.64, p<0.001) and oligoprogression (HR=3.84, p<0.001) were independent predictors for early PMR. Risk groups were identified with median PMR-free survival ranging from 5 months to not yet reached at the time of analysis. Rates of 3-year OS were 0%, 53% (95% confidence interval [CI] 48 - 58), 77% (95% CI 73 - 81) and 93% (95% CI 90 - 96) in groups 1-4, respectively (p<0.001). CONCLUSION Four distinct risk groups for early PMR are identified, which differ significantly in PMR-free survival and overall survival. The group with all three risk factors had a median PMR-free survival of 5 months and may not benefit from local ablative therapy alone. This model should be externally validated with data from other prospective trials.
Collapse
Affiliation(s)
- S Baker
- University of British Columbia; BC Cancer, Surrey.
| | - B Mou
- University of British Columbia; BC Cancer, Kelowna
| | - W Jiang
- University of British Columbia; BC Cancer, Surrey
| | - M Liu
- University of British Columbia; BC Cancer, Vancouver
| | | | | | | | - H Carolan
- University of British Columbia; BC Cancer, Vancouver
| | - S Atrchian
- University of British Columbia; BC Cancer, Kelowna
| | - T Berrang
- University of British Columbia; BC Cancer, Victoria
| | - A Bang
- University of British Columbia; BC Cancer, Victoria
| | | | | | - S Tyldesley
- University of British Columbia; BC Cancer, Vancouver
| | - R A Olson
- University of British Columbia; BC Cancer, Prince George.
| |
Collapse
|
52
|
Baker S, Jiang W, Mou B, Lund CR, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Chng N, Matthews Q, Arbour G, Benny A, Tyldesley S, Olson RA. Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys 2022; 114:617-626. [PMID: 35667528 DOI: 10.1016/j.ijrobp.2022.05.033] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 05/09/2022] [Accepted: 05/23/2022] [Indexed: 11/29/2022]
Abstract
PURPOSE Despite increasing utilization of stereotactic ablative therapy (SABR) for oligometastatic cancer, prospective outcomes are lacking. The purpose of this study was to determine progression-free survival (PFS), local control (LC) and prognostic factors from the population-based phase II XXX trial. METHODS AND MATERIALS The XXX trial was a single arm phase II study with the primary endpoint of toxicity, conducted at the 6 regional cancer centres across XXX, during which time SABR for oligometastases was only offered on trial. Patients with up to 5 oligometastases (total or not controlled by prior treatment, and including induced oligometastatic disease) underwent SABR to all lesions. Patients were 18 years of age or older, ECOG 0-2 and had life expectancy ≥ 6 months. The secondary outcomes of PFS and LC are presented here. RESULTS Between November 2016 and July 2020, 381 patients underwent SABR on trial. Median follow-up was 27 months (IQR 18-36). Median PFS was 15 months (95% CI 12-18). LC at 1 and 3 years were 93% (95% CI 91 - 95) and 87% (95% CI 84 - 90), respectively. On multivariable analysis, increasing tumor diameter (HR=1.09, p<0.001), declining performance status (HR=2.13, p<0.001), disease-free interval < 18 months (HR=1.52, p=0.003), four or more metastases at SABR (HR=1.48, p=0.048), initiation or change in systemic treatment (HR=0.50, p<0.001) and oligoprogression (HR=1.56, p=0.008) were significant independent predictors of PFS. Tumor diameter (SHR=1.28, p<0.001), colorectal histology (SHR=4.33, p=0.002) and "other" histology (SHR=3.90, p<0.001) were associated with worse local control. CONCLUSIONS In this population-based cohort including patients with genuine oligometastatic, oligoprogressive, and induced oligometastatic disease, the median PFS was 15 months and LC at 3 years was 87%. This supports ongoing efforts to randomize patients on phase III trials, even outside the original 1-5 metachronous oligometastatic paradigm.
Collapse
Affiliation(s)
- S Baker
- University of British Columbia; BC Cancer - Surrey
| | - W Jiang
- University of British Columbia; BC Cancer - Surrey
| | - B Mou
- University of British Columbia; BC Cancer - Kelowna
| | - C R Lund
- University of British Columbia; BC Cancer - Surrey
| | - M Liu
- University of British Columbia; BC Cancer - Vancouver
| | | | | | - A S Alexander
- University of British Columbia; BC Cancer - Victoria
| | - H Carolan
- University of British Columbia; BC Cancer - Vancouver
| | - S Atrchian
- University of British Columbia; BC Cancer - Kelowna
| | - N Chng
- BC Cancer - Prince George
| | | | | | - A Benny
- University of British Columbia
| | - S Tyldesley
- University of British Columbia; BC Cancer - Vancouver
| | - R A Olson
- University of British Columbia; BC Cancer - Prince George.
| |
Collapse
|
53
|
Fang Z, Jiang W, Ye L. P-235 Elevated protein tyrosine phosphatase kappa expression is associated with disease progression and poor prognosis of pancreatic cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
54
|
Gao H, Benedikt J, Jiang W, Martin T. P-211 Claudin-16, its clinical and prognostic value in colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
55
|
Asharaf H, Xu Y, Ye L, Jiang W. P-293 Increased expression of dual-specificity phosphatase 7 in gastric cancer is associated with poor prognosis and chemoresistance. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
56
|
Zeng J, Sanders A, Hargest R, Ye L, Jiang W. P-266 Expression of HSP60 in colorectal cancer and implication in chemotherapeutic responses. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
57
|
Sui L, Zeng J, Ye L, Martin T, Jiang W, Hargest R. P-282 Impact of death-associated protein-3 (DAP3) and DAP3 binding cell death enhancer 1 (DELE1) on drug sensitivity in colorectal cancer cells. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
58
|
Tang KN, Chen XL, Zhang WH, Yang K, Liu K, Jiang W, Chen XZ, Hu JK. [Comparison of postoperative mid-term and long-term quality of life between Billroth-I gastroduodenostomy and Billroth-II gastrojejunostomy after radical distal gastrectomy in patients with gastric cancer: a cohort study based on a case registry database]. Zhonghua Wei Chang Wai Ke Za Zhi 2022; 25:401-411. [PMID: 35599395 DOI: 10.3760/cma.j.cn441530-20220304-00081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: The pattern of digestive tract reconstruction in radical gastrectomy for gastric cancer is still inconclusive. This study aims to compare mid-term and long-term quality of life after radical gastrectomy for distal gastric cancer between Billroth-I (B-I) and Billroth-II (B-II) reconstruction. Methods: A retrospective cohort study was conducted.Clinicopathological and follow-up data of 859 gastric cancer patients were colected cellected from the surgical case registry database of Gastrointestinal Surgery Center of Sichuan University West China Hospital, who underwent radical distal gastric cancer resection between January 2016 and December 2020. Inclusion criteria: (1) gastric cancer confirmed by preoperative gastroscopy and biopsy; (2) elective radical distal major gastrectomy performed according to the Japanese Society for Gastric Cancer treatment guidelines for gastric cancer; (3) TNM staging referenced to the American Cancer Society 8th edition criteria and exclusion of patients with stage IV by postoperative pathology; (4) combined organ resection only involving the gallbladder or appendix; (5) gastrointestinal tract reconstruction modality of B-I or B-II; (6) complete clinicopathological data; (7) survivor during the last follow-up period from December 15, 2021 to January 15, 2022. Exclusion criteria: (1) poor compliance to follow-up; (2) incomplete information on questionnaire evaluation; (3) survivors with tumors; (4) concurrent malignancies in other systems; (5) concurrent psychiatric and neurological disorders that seriously affected the objectivity of the questionnaire or interfered with patient's cognition. Telephone follow-up was conducted by a single investigator from December 2021 to January 2022, and the standardized questionnaire EORTC QLQ-C30 scale (symptom domains, functional domains and general health status) and EORTC QLQ-STO22 scale (5 symptoms of dysphagia, pain, reflux, restricted eating, anxiety; 4 single items of dry mouth, taste, body image, hair loss) were applied to evaluate postoperative quality of life. In 859 patients, 271 were females and 588 were males; the median age was 57.0 (49.5, 66.0) years. The included cases were divided into the postoperative follow-up first year group (202 cases), the second year group (236 cases), the third year group (148 cases), the fourth year group (129 cases) and the fifth year group (144 cases) according to the number of years of postoperative follow-up. Each group was then divided into B-I reconstruction group and B-II reconstruction group according to procedure of digestive tract reconstruction. Except for T-stage in the fourth year group, and age, tumor T-stage and tumor TNM-stage in the fifth year group, whose differences were statistically significant between the B-I and B-II reconstruction groups (all P<0.05), the differences between the B-I and B-II reconstruction groups in terms of demographics, body mass index (BMI), tumor TNM-stage and tumor pathological grading in postoperative follow-up each year group were not statistically significant (all P>0.05), suggesting that the baseline information between B-I reconstruction group and the B-II reconstruction group in postoperative each year group was comparable. Evaluation indicators of quality of life (EORTC QLQ-C30 and EORTC QLQ-STO22 scales) and nutrition-related laboratory tests (serum hemoglobin, albumin, total protein, triglycerides) between the B-I reconstruction group and B-II reconstruction group in each year group were compared. Non-normally distributed continuous variables were presented as median (Q(1),Q(3)), and compared by using the Wilcoxon rank sum test (paired=False). The χ(2) test or Fisher's exact test was used for comparison of categorical variables between groups. Results: There were no statistically significant differences in all indexes EORTC QLQ-30 scale between the B-I reconstruction group and the B-II reconstruction group among all postoperative follow-up year groups (all P>0.05). The EORTC QLQ-STO22 scale showed that significant differences in pain and eating scores between the B-I reconstruction group and the B-II reconstruction group were found in the second year group, and significant differences in eating, body and hair loss scores between the B-I reconstruction group and the B-II reconstruction group were found in the third year group (all P<0.05), while no significant differences of other item scores between the B-I reconstruction group and the B-II reconstruction group were found in postoperative follow-up of all year groups (P>0.05). Triglyceride level was higher in the B-II reconstruction group than that in the B-I reconstruction group (W=2 060.5, P=0.038), and the proportion of patients with hyperlipidemia (triglycerides >1.85 mmol/L) was also higher in the B-II reconstruction group (19/168, 11.3%) than that in the B-I reconstruction group (0/34) (χ(2)=0.047, P=0.030) in the first year group with significant difference. Albumin level was lower in the B-II reconstruction group than that in the B-I reconstruction group (W=482.5, P=0.036), and the proportion of patients with hypoproteinemia (albumin <40 g/L) was also higher in the B-II reconstruction group (19/125, 15.2%) than that in the B-I reconstruction group (0/19) in the fifth year group, but the difference was not statistically significant (χ(2)=0.341, P=0.164). Other nutrition-related clinical laboratory tests were not statistically different between the B-I reconstruction and the B-II reconstruction in each year group (all P>0.05). Conclusions: The effects of both B-I and B-II reconstruction methods on postoperative mid-term and long-term quality of life are comparable. The choice of reconstruction method after radical resection of distal gastric cancer can be based on a combination of patients' condition, sugenos' eoperience and operational convenience.
Collapse
Affiliation(s)
- K N Tang
- Department of Gastrointestinal Surgery and Gastric Cancer Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China University of Electronic Science and Technology of China Hospital, Chengdu 611731, China
| | - X L Chen
- Department of Gastrointestinal Surgery and Gastric Cancer Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China
| | - W H Zhang
- Department of Gastrointestinal Surgery and Gastric Cancer Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China
| | - K Yang
- Department of Gastrointestinal Surgery and Gastric Cancer Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China
| | - K Liu
- Department of Gastrointestinal Surgery and Gastric Cancer Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China
| | - W Jiang
- University of Electronic Science and Technology of China Hospital, Chengdu 611731, China
| | - X Z Chen
- Department of Gastrointestinal Surgery and Gastric Cancer Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China The Second People's hospital of Yibin, Yibin 644000, China
| | - J K Hu
- Department of Gastrointestinal Surgery and Gastric Cancer Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China
| |
Collapse
|
59
|
Shang L, Jiang W, Zhang J, Wu W. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:665-672. [PMID: 35673909 DOI: 10.12122/j.issn.1673-4254.2022.05.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the role of proline 4-hydroxylase Ⅱ (P4HA2) in the occurrence and progression of liver cancer. METHODS GEPIA and Human Protein Atlas database were used to predict the expression of P4HA2 in hepatocellular carcinoma (HCC), and K-M plotter online database was used to analyze the relationship between P4HA2 expression and the prognosis of HCC. We also examined the expressions of P4HA2 in HCC cells and normal hepatocytes using qRT-PCR and Western blotting. With lentivirus-mediated RNA interference, P4HA2 expression was knocked down in hepatoma SNU-449 and Hep-3B cells, and the changes in cell proliferation, migration and invasion were assessed using cell counting kit-8 (CCK-8) assay, colony formation test, scratch test and Transwell assay. The changes in the expressions of epithelial-mesenchymal transition (EMT) and PI3K/Akt/mTOR signal pathway-related proteins were detected using Western blotting. RESULTS Online database analysis showed that the expression of P4HA2 was significantly higher in HCC tissues than in normal liver tissues (P < 0.05). The expression levels of P4HA2 mRNA and protein were also significantly higher in HCC cell lines than in normal hepatocytes (P < 0.01). Lentivirus-mediated RNA interference of P4HA2 significantly lowered the expression levels of P4HA2 mRNA and protein in the hepatoma cells (P < 0.05) and caused obvious inhibition of cell proliferation, migration and invasion. P4HA2 knockdown significantly increased the expression of E-cadherin protein, lowered the expressions of N-cadherin and Snail, and obviously decreased the expressions of phosphorylated PI3K, AKT and mTOR (P < 0.05). CONCLUSION P4HA2 enhances the proliferation, migration, invasion, and EMT of hepatoma cells by activating the PI3K/Akt/mTOR signaling pathway to promote the occurrence and progression of liver cancer.
Collapse
Affiliation(s)
- L Shang
- Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, School of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China
| | - W Jiang
- Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, School of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China
| | - J Zhang
- Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, School of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China
| | - W Wu
- Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, School of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China.,Department of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China
| |
Collapse
|
60
|
Jiang P, Qu A, Jiang W, Deng X, Wang J. PO-1340 Phase Ⅰ Trail of Concurrent Nab-paclitaxel and Cisplatin with VMAT for LACC. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03304-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
61
|
Liang L, Jiang W, Zheng Y, Liu TS, Shen XZ, Chen YJ. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer. J Physiol Pharmacol 2022; 73. [PMID: 35988929 DOI: 10.26402/jpp.2022.2.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 04/30/2022] [Indexed: 06/15/2023]
Abstract
Whether tumor mutational burden (TMB), which refers to the total number of somatic or acquired mutations per million bases in a particular region of the tumor genome, can serve as a predictive biomarker of immune checkpoint inhibitor (ICI) therapy for colon cancer remains unclear. Hereby, we retrospectively investigated the differentially expressed genes (DEGs) based on the level of TMB and tried to established a risk score model as a novel biomarker. The DNA mutation data were retrieved from the Masked Somatic Mutation in Genomic Data Commons data portal of the Cancer Genome Atlas, where the RNA sequencing data, clinical information, and survival outcomes of patients were downloaded. Patients with incomplete clinical information were excluded. The immune score and stromal score were calculated to investigate immune infiltration. The patients were grouped into TMB-high group and the TMB-low group based on the median value of TMB. An immune relevant gene set was obtained from the Immunology Database and Analysis Portal to identify immune-related DEGs. The Cox proportional hazard model and nomogram were applied to establish the risk model. In results: the TMB value was associated with age (p≤0.001), clinical stage (p≤0.001), N stage (p≤0.001), M stage (p=0.003), and immune score (p≤0.001). Twenty-nine immune-related DEGs were identified as enriched in immune response-related function or pathway and tumorigenesis signaling. Nine of 29 were determined to establish a riskScore model. The riskScore suggested a positive relationship with the TMB value (p=0.033), immune score (p≤0.001), and tumor immune dysfunction and exclusion (TIDE) (p=0.002) and presented an independent prognostic factor (p≤0.001, HR=1.04), which predicted the overall survival with good specificity. We concluded that the combination of TMB with transcriptome expression has a predictive and prognostic value for patients treated with ICIs.
Collapse
Affiliation(s)
- L Liang
- Department of Medical Oncology, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
- Cancer Center, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
- Center of Evidence Medicine, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
| | - W Jiang
- Department of Gastroenterology, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
- Department of Gastroenterology, Xiamen Branch, Zhongshan Hospital of Fudan University, Xiamen, Huli District, Fujian, People's Republic of China
| | - Y Zheng
- Department of Gastroenterology, Xiamen Branch, Zhongshan Hospital of Fudan University, Xiamen, Huli District, Fujian, People's Republic of China
| | - T S Liu
- Department of Medical Oncology, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
- Cancer Center, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
- Center of Evidence Medicine, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
| | - X Z Shen
- Department of Gastroenterology, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China
| | - Y J Chen
- Department of Gastroenterology, Zhongshan Hospital of Fudan University, Xuhui District, Shanghai, People's Republic of China.
| |
Collapse
|
62
|
Ding Y, Jiang J, Xu J, Chen Y, Zheng Y, Jiang W, Mao C, Jiang H, Bao X, Shen Y, Li X, Teng L, Xu N. Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open 2022; 7:100407. [PMID: 35248824 PMCID: PMC8897579 DOI: 10.1016/j.esmoop.2022.100407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 01/22/2022] [Accepted: 01/25/2022] [Indexed: 12/01/2022] Open
Abstract
Background Cancer of unknown primary site (CUP) is a term applied to characterize pathologically confirmed metastatic cancer with unknown primary tumor origin. It remains uncertain whether patients with CUP benefit from site-specific therapy guided by molecular profiling. Patients and methods A systematic search in PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov, and of conference abstracts from January 1976 to January 2021 was performed to identify studies investigating the efficacy of site-specific therapy on patients with CUP. The quality of included studies was evaluated using the Cochrane risk of bias tool and Newcastle–Ottawa scale. Eligible studies were weighted and pooled for meta-analysis. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were assessed to compare the efficacy of site-specific therapy with empiric therapy in patients with CUP. In addition, subgroup analyses were conducted. Results Five studies comprising 1114 patients were identified, of which 454 patients received site-specific therapy, and 660 patients received empiric therapy. Our meta-analysis revealed that site-specific therapy was not significantly associated with improved PFS [HR 0.93, 95% confidence interval (CI) 0.74-1.17, P = 0.534] and OS (HR 0.75, 95% CI 0.55-1.03, P = 0.069), compared with empiric therapy. However, during subgroup analysis significantly improved OS was associated with site-specific therapy in the high-accuracy predictive assay subgroup (HR 0.46, 95% CI 0.26-0.81, P = 0.008) compared with the low accuracy predictive assay subgroup (HR 0.93, 95% CI 0.75-1.15, P = 0.509). Furthermore, compared with patients with less responsive tumor types, more survival benefit from site-specific therapy was found in patients with more responsive tumors (HR 0.67, 95% CI 0.46-0.97, P = 0.037). Conclusions Our results suggest that site-specific therapy is not significantly associated with improved survival outcomes; however, it might benefit patients with CUP with responsive tumor types. Studies evaluating the role of site-specific therapy guided by molecular profiling in CUP provided contradictory results. Site-specific therapy is not significantly associated with improved survival outcomes in the overall CUP population. Molecularly defined site-specific therapy may improve OS only when high-accuracy assays assign CUP to responsive tumor types.
Collapse
Affiliation(s)
- Y Ding
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - J Jiang
- Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - J Xu
- Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Y Chen
- Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Y Zheng
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - W Jiang
- Department of Colorectal Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou; China
| | - C Mao
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - H Jiang
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - X Bao
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Y Shen
- Centre of Clinical Laboratory, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou; China; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou; China; Institute of Laboratory Medicine, Zhejiang University, Hangzhou; China
| | - X Li
- Department of Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - L Teng
- Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
| | - N Xu
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
| |
Collapse
|
63
|
Jiang W, Liang JP. [Overview of technical advances in the diagnosis of pulp and periapical diseases]. Zhonghua Kou Qiang Yi Xue Za Zhi 2022; 57:227-232. [PMID: 35279999 DOI: 10.3760/cma.j.cn112144-20211111-00497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Pulp and periapical diseases are common and frequently occurring diseases of which diagnosis and treatment must be dealt with by the dental clinicians. The diagnostic techniques of these diseases include evaluation of pulp vitality, measurement of pulp blood circulation and analysis and judgment of root canal anatomy. With the continuous emergence of digital and imaging technologies, the correct application of these technologies in clinic will help clinicians improve their abilities in diagnosis and treatment of related diseases. The present article summarizes and reviews the progress of assistant technology for diagnosing dental pulp and periapical diseases in recent years and puts forward some suggestions for its application.
Collapse
Affiliation(s)
- W Jiang
- Department of Endodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine & College of Stomatology, Shanghai Jiao Tong University & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
| | - J P Liang
- Department of Endodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine & College of Stomatology, Shanghai Jiao Tong University & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
| |
Collapse
|
64
|
Yao J, Zhang W, Wang J, Wang K, Lv C, Zhang Z, Chen X, Chen Y, Jiang W, Niu J, Song F, Liu P, Sun D. The Status of Iodine Nutrition after Removing Iodized Salt in High Water Iodine Regions: a Cross-sectional Study in China. Biol Trace Elem Res 2022; 200:1020-1031. [PMID: 33929694 DOI: 10.1007/s12011-021-02727-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 04/15/2021] [Indexed: 11/29/2022]
Abstract
Currently, the removal of iodized salt is carried out in high water iodine regions. The present situation of iodine nutrition and the prevalence of thyroid diseases in such regions have not been clearly elucidated. This study aimed to figure out these problems to help render effective measures for cases of abnormal iodine nutrition status. A cross-sectional study was carried out in four areas of Jining and Heze, Shandong Province, China, with different water iodine concentrations (WIC). In total, 1344 adults were enrolled in this study, and data related to their iodine nutrition, thyroid function, and thyroid ultrasonography were collected. Subjects were grouped according to WIC, urine iodine concentration (UIC), serum iodine concentration (SIC), and combined UIC and SIC for analysis. Iodine levels were in excess in the 100 μg/L ≤ WIC < 300 μg/L and WIC ≥ 300 μg/L areas. Compared with the control WIC group (10-100 μg/L), the WIC ≥ 300 μg/L group had a higher prevalence of thyroid autoimmunity (TAI, 21.25% vs. 13.19%, P <0.05), subclinical hypothyroidism (SH, 20.20% vs. 11.96%, P < 0.05), thyroid nodules (TN, 31.75% vs. 18.71%, P < 0.05), and thyroid dysfunction (23.62% vs. 12.26%, P < 0.05). Compared with the UIC control group (100-300 μg/L), high UIC group (≥ 800 μg/L) had a higher prevalence of TN (33.75% vs. 21.14%, P < 0.05) and thyroid dysfunction (25% vs. 14.47%, P < 0.05). Next, compared with the control SIC group (50-110 μg/L), high SIC group (≥ 110 μg/L) had a higher prevalence of TAI (33.80% vs. 14.47%, P < 0.05), SH (23.94% vs. 14.30%, P < 0.05), and thyroid dysfunction (33.80% vs. 15.29%, P < 0.05). Finally, subjects with the highest UIC and the highest SIC also had a higher prevalence of TAI (25.92% vs. 10.97%, P < 0.05), SH (23.45% vs. 10.97%, P < 0.05), TN (34.56% vs. 15.85%, P < 0.05), and thyroid dysfunction (27.16% vs. 13.41%, P < 0.05) than subjects with middle iodine levels. The iodine nutrition of subjects in the WIC ≥ 300 μg/L areas was still in excess after removing iodized salt from their diets. High levels of iodine also increased the prevalence of TAI, SH, TN, and thyroid dysfunction in those areas. Simply removing iodized salt may not be sufficient for high water iodine regions.
Collapse
Affiliation(s)
- J Yao
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - W Zhang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - J Wang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - K Wang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - C Lv
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - Z Zhang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - X Chen
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - Y Chen
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - W Jiang
- Institute of Endemic Disease Control, Jinan, Shandong Province, China
| | - J Niu
- Heze Center for Disease Control and Prevention, Heze, China
| | - F Song
- Jining Center for Disease Control and Prevention, Jining, China
| | - P Liu
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - D Sun
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China.
| |
Collapse
|
65
|
Affiliation(s)
- Hui Yuan
- College of Chemistry and Environmental Technology Wuhan Institute of Technology Wuhan China
| | - Xuejun Yu
- Three Gorges Public Inspection and Testing Center China
| | - Wenxiu Jiang
- College of Chemistry and Environmental Technology Wuhan Institute of Technology Wuhan China
| | - Bowei Shen
- College of Chemistry and Environmental Technology Wuhan Institute of Technology Wuhan China
| | - Farong Zhang
- College of Chemistry and Environmental Technology Wuhan Institute of Technology Wuhan China
| | - Zhiquan Pan
- College of Chemistry and Environmental Technology Wuhan Institute of Technology Wuhan China
- Three Gorges Public Inspection and Testing Center China
| | - Hong Zhou
- College of Chemistry and Environmental Technology Wuhan Institute of Technology Wuhan China
| |
Collapse
|
66
|
Xie R, Shang B, Jiang W, Cao C, Shi H, Shou J. Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00470-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
67
|
Cao C, Shou J, Sun Z, Zhou A, Lan X, Shang B, Jiang W, Guo L, Zheng S, Bi X. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01205-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
68
|
Zhai L, Jiang W, Zang Y, Gao Y, Jiang D, Tian Q, Zhao C. Impact of Thyroid Tissue Status on the Cut-Off Value of Lymph Node Fine-Needle Aspiration Thyroglobulin Measurements in Papillary Thyroid Cancer. Br J Biomed Sci 2022; 79:10210. [PMID: 35996517 PMCID: PMC8915611 DOI: 10.3389/bjbs.2021.10210] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 12/02/2021] [Indexed: 11/13/2022]
Abstract
Objective: To study the optimal cut-off value of thyroglobulin measurement in a fine-needle aspiration (FNA-Tg) in diagnosing malignant lymph nodes and benign lymph nodes (LNs) according to the thyroid tissue status. Methods: A total of 517 LNs were aspirated: 401 preoperative LNs, 42 LNs after subtotal thyroidectomy and 74 suspected LNs after total thyroidectomy. The cut-off value of FNA-Tg was obtained from receiver operating characteristic (ROC) analysis. The cut-off value with the best diagnostic performance was then obtained by comparing different cut-off values from other studies. Results: LN FNA-Tg levels differed between preoperative and total thyroid disease (p < 0.001) and subtotal thyroidectomy and total thyroidectomy (p = 0.03), but not between preoperative and subtotal thyroidectomy (p = 1.00). Accordingly, those 443 LNs with preoperative and subtotal thyroidectomy were compared to those 74 without thyroid tissue. The optimal cut-off value in thyroid tissue group was 19.4 ng/ml and the area under the ROC curve (AUC) was 0.95 (95% CI 0.92–0.97). The optimal cut-off value in thyroid tissue absence group was 1.2 ng/ml and the AUC was 0.93 (0.85–0.98). After the analysis and comparison of multiple cut-off values, the optimal diagnostic performance was still found to be 19.4 ng/ml and 1.2 ng/ml. Conclusion: The influential factors of FNA-Tg are still controversial, and the optimal cut-off value of FNA-Tg can be determined based on the presence or absence of thyroid tissue. FNA-Tg can be used as an important auxiliary method for diagnosing cervical metastatic LNs of thyroid cancer.
Collapse
Affiliation(s)
- L. Zhai
- Department of Abdominal Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, China
- Department of Ultrasound, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China
| | - W. Jiang
- Health Management Center, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Y. Zang
- Department of Abdominal Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Y. Gao
- Department of Abdominal Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - D. Jiang
- Department of Abdominal Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Q. Tian
- Department of Laboratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - C. Zhao
- Department of Abdominal Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, China
- *Correspondence: C. Zhao,
| |
Collapse
|
69
|
Zhou J, Li T, Chen X, Wang M, Jiang W, Jia H. Comparison of the Diagnostic Value of SARC-F and Its Three Modified Versions for Screening Sarcopenia in Chinese Community-Dwelling Older Adults. J Nutr Health Aging 2022; 26:77-83. [PMID: 35067707 DOI: 10.1007/s12603-021-1718-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVES Sarcopenia refers to age-related loss of skeletal muscle mass. SARC-F is a screening tool for sarcopenia with high specificity and relatively good overall diagnostic accuracy but with low sensitivity. This study evaluated the diagnostic utility of SARC-F and its three modified versions (SARC-CalF, SARC-F+AC, and SARC-CalF+AC) for screening sarcopenia in community-dwelling older adults. DESIGN Diagnostic accuracy study. SETTINGS AND PARTICIPANTS We screened sarcopenia of older adults (age ≥ 60 years) in three communities in 2020. The participants' information and anthropometric measurements were collected, respectively. METHODS The updated consensuses of AWGS2019 and the EWGSOP2 were applied as the reference standards. we performed sensitivity/specificity analyses and estimated the areas under the receiver operating characteristic curves (AUCs) of the four scales. RESULTS The prevalence of sarcopenia was 26.4% and 12.5% based on the AWGS2019 and EWGSOP2 criteria, respectively. The sensitivities/specificities of SARC-F, SARC-CalF, SARC-F+AC, and SARC-CalF+AC were 12.26%/95.59%, 47.17%/91.53%, 82.08%/68.47%, and 75.47%/83.73%, respectively, using the AWGS2019 criteria. Further, the corresponding AUCs of SARC-F, SARC-CalF, SARC-F+AC, and SARC-CalF+AC were 0.650 (95% confidence interval [CI]: 0.601-0.697), 0.811 (95% CI: 0.769-0.848), 0.801 (95% CI: 0.759-0.839), and 0.848 (95% CI: 0.809-0.881), respectively. Using the EWGSOP2 criteria, the sensitivities/specificities of SARC-F, SARC-CalF, SARC-F+AC, and SARC-CalF+AC were 20.00%/95.44%, 56.00%/86.61%, 70.00%/81.20%, and 80.00%/74.93%, respectively. The AUCs of SARC-F, SARC-CalF, SARC-F+AC, and SARC-CalF+AC were 0.706 (95% CI: 0.659-0.750), 0.799 (95% CI: 0.756-0.837), 0.815 (95% CI: 0.774-0.852), and 0.834 (95% CI: 0.794-0.869), respectively. CONCLUSIONS The modified versions of SARC-F+AC and SARC-CalF+AC, which have superior sensitivity, can be used to screen sarcopenia in community-dwelling older adults. SARC-CalF+AC had the highest overall diagnostic accuracy for screening sarcopenia among community-dwelling older adults.
Collapse
Affiliation(s)
- J Zhou
- Hong Jia, School of Public Health, Southwest Medical University, Luzhou City, Sichuan Province, China,
| | | | | | | | | | | |
Collapse
|
70
|
Ding X, Jiang W, Hu YH, Jiang J, Wu Y, Xu CZ, Wu ZZ, Yu YF, Liu XJ, Li GW, Yin DP. [Study on the incidence of adult herpes zoster in Yichang city and its association with early-life famine exposure]. Zhonghua Yu Fang Yi Xue Za Zhi 2021; 55:1328-1331. [PMID: 34749477 DOI: 10.3760/cma.j.cn112150-20201110-01350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Based on Yichang health big data platform, 850 608 patients from September 2018 to September 2019 were included in this study. According to the date of birth, the participants were divided into early childhood famine exposure group, fetal famine exposure group and non-famine exposure group. The incidence of adult herpes zoster (HZ) in Yichang city was analyzed, and the correlation between early life famine exposure and adult HZ was analyzed. In 2019, the crude incidence rate of adult HZ in Yichang was 6.83‰. The crude incidence rate of adult HZ in females (7.26‰) was higher than that in males (6.40‰). Compared with the non-famine exposure group, fetal famine exposure was associated with the incidence of adult HZ (OR=1.21; 95%CI: 1.01-1.45, P=0.041). After stratification by sex, fetal famine exposure was only found to be associated with the onset of adult HZ in females (OR=1.28, 95%CI:1.02-1.61, P=0.034).
Collapse
Affiliation(s)
- X Ding
- School of Public Health, North China University of Science and Technology, Tangshan 063210,China
| | - W Jiang
- Yichang Center for Disease Control and Prevention, Yichang 443003,China
| | - Y H Hu
- Chinese Center for Disease Control and Prevention, Beijing 102206,China Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing 100083,China
| | - J Jiang
- Yichang Center for Disease Control and Prevention, Yichang 443003,China
| | - Y Wu
- School of Public Health, North China University of Science and Technology, Tangshan 063210,China
| | - C Z Xu
- Yichang Center for Disease Control and Prevention, Yichang 443003,China
| | - Z Z Wu
- Yichang Center for Disease Control and Prevention, Yichang 443003,China
| | - Y F Yu
- Yichang Center for Disease Control and Prevention, Yichang 443003,China
| | - X J Liu
- Yichang Center for Disease Control and Prevention, Yichang 443003,China
| | - G W Li
- Yichang Center for Disease Control and Prevention, Yichang 443003,China
| | - D P Yin
- Chinese Center for Disease Control and Prevention, Beijing 102206,China
| |
Collapse
|
71
|
Kiyanda A, Mensah S, Patts G, Cheng D, Jiang W, Samet J, So-Armah K. Change in alcohol consumption and altered coagulation in people with HIV (PWH). Alcohol 2021. [DOI: 10.1016/j.alcohol.2021.09.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
72
|
Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Huang V, Mestrovic T, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S. Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
73
|
Zhou Y, Yu Y, Ke R, Jiang W, Xu M, Xiao C, Cheng Y, Li Z, Li B, Wang Z, Li J, Duan X, Ye M. Design of a Lyman-Alpha-Based BES for edge plasma density diagnosing on the HL-2A tokamak. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
74
|
Chen B, Shi H, Zhang J, Zhou C, Han M, Jiang W, Lai Y, Tu X, Li H. CRISPR-based RNA-binding protein mapping in live cells. Biochem Biophys Res Commun 2021; 583:79-85. [PMID: 34735883 DOI: 10.1016/j.bbrc.2021.10.059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 10/24/2021] [Indexed: 12/26/2022]
Abstract
RNA-binding proteins (RBPs) are involved in all aspects of RNA metabolism, and RNA-RBP interactions are important for cell homeostasis and viral replication. The global RNA-binding proteome was recently reported; however, little is known about the proteins that bind to specific RNAs. In this study, we describe a novel CRISPR-based RNA interaction proteomics method in live cells. In brief, dCas13a with an HA tag was expressed in cells and bound to an RNA of interest with the help of gRNA. The RNA-protein complexes physically bound to dCas13a-HA were crosslinked using UV light and captured using anti-HA beads, after which the proteins were purified and identified using mass spectrometry. We optimized this system and subsequently applied it to U1 small nuclear RNA, which revealed 226 proteins.
Collapse
Affiliation(s)
- Baiwen Chen
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital,Fudan University, Shanghai, 200031, China
| | - Haiyan Shi
- Department of ER, CHINA RESOURCES & WISCO GENERAL HOSPITAL, Wuhan University of Science and Technology, No.209 Metallurgical Avenue, Qingshan District, Wuhan, Hubei, 430080, China
| | - Jia Zhang
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital,Fudan University, Shanghai, 200031, China
| | - Chun Zhou
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital,Fudan University, Shanghai, 200031, China
| | - Miaomiao Han
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital,Fudan University, Shanghai, 200031, China
| | - Wenxiu Jiang
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital,Fudan University, Shanghai, 200031, China
| | - Yuting Lai
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital,Fudan University, Shanghai, 200031, China
| | - Xia Tu
- Department of ER, CHINA RESOURCES & WISCO GENERAL HOSPITAL, Wuhan University of Science and Technology, No.209 Metallurgical Avenue, Qingshan District, Wuhan, Hubei, 430080, China.
| | - Huabin Li
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital,Fudan University, Shanghai, 200031, China.
| |
Collapse
|
75
|
Qin Y, Sun XL, Wang D, Jiang W, Wang HY, Sun XX, Fang W, Li J, Tian Z, Song L, Kang LM. [A case of wild-type transthyretin cardiac amyloidosis]. Zhonghua Xin Xue Guan Bing Za Zhi 2021; 49:1023-1026. [PMID: 34674441 DOI: 10.3760/cma.j.cn112148-20201204-00961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Y Qin
- Department of Cardiomyopathy, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - X L Sun
- Department of Cardiomyopathy, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - D Wang
- Department of Cardiomyopathy, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - W Jiang
- Department of Cardiomyopathy, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - H Y Wang
- Department of Pathology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - X X Sun
- Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - W Fang
- Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - J Li
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| | - Z Tian
- Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| | - L Song
- Department of Cardiomyopathy, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - L M Kang
- Department of Cardiomyopathy, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| |
Collapse
|
76
|
Morrone D, Chen C, Dinshaw L, Jiang W, Kim YH, Kirchhof P, Koretsune Y, Pecen L, Reimitz PE, Wang CC, Yamashita T, Unverdorben M, De Caterina R. Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The ESC atrial fibrillation management guidelines recommend a risk-based approach to oral anticoagulant (OAC) therapy. How clinical practice aligns with these recommendations is of interest.
Purpose
To analyse real world data from Global ETNA-AF program in patient groups stratified by stroke and bleeding risk scores according to ESC guidelines.
Methods
Global ETNA-AF is a multicentre, prospective, noninterventional program evaluating the safety and effectiveness of edoxaban in patients from European and Asian countries. Baseline characteristics and clinical event data at 2-year follow-up were analysed in 4 subgroups defined by CHA2DS2-VASc score (≥3 for female / ≥2 for male [OAC recommended] vs 2 for female / 1 for male [OAC should be considered]) and HAS-BLED score (≥3 [Bleeding risk high] vs <3 [Bleeding risk low]) (Table 1).
Results
Of 27,616 patients included in this analysis, 23,152 (83.8%) were in the “OAC recommended” category and 3,539 (12.8%) were in the “OAC should be considered” category. Only 3.3% of patients did not meet ESC guideline criteria for OAC initiation. Among patients with high bleeding risk, 98% were in the “OAC recommended” category. A similar distribution was observed across regions (Table 2). The recommended edoxaban dose was used in the vast majority (>80%) of patients across all risk stratification subgroups. In the “OAC recommended” category, patients with high bleeding risk had higher rates of thromboembolic, bleeding, and death events than those with low bleeding risk.
Conclusion
Data from routine clinical practice in Global ETNA-AF demonstrate high concordance of edoxaban treatment with ESC guidelines. Edoxaban dose is consistent with label recommendation in the vast majority (>80%) of patients. Clinical event rates were generally low across all risk groups, including acceptable bleeding rates in anticoagulated patients with high bleeding risk.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Table 1. Subgroups as per ESC guidelinesTable 2. Patient characteristics & events
Collapse
Affiliation(s)
- D Morrone
- University Hospital of Pisa, Pisa, Italy
| | - C Chen
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| | - L Dinshaw
- University Heart Center Hamburg, Hamburg, Germany
| | - W Jiang
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| | - Y.-H Kim
- Korea University, Seoul, Korea (Republic of)
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - Y Koretsune
- National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - L Pecen
- Institute of Computer Science of the Czech Academy of Science, Prague, Czechia
| | - P.-E Reimitz
- Daiichi Sankyo Europe GmbH, Clinical Operations and Biostatistics and Data Operations, Munich, Germany
| | - C.-C Wang
- Korea University, Seoul, Korea (Republic of)
| | - T Yamashita
- National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - M Unverdorben
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| | | |
Collapse
|
77
|
Dinshaw L, Chen C, De Caterina R, Jiang W, Kim YH, Koretsune Y, Morrone D, Pecen L, Reimitz PE, Wang CC, Yamashita T, Unverdorben M, Kirchhof P. Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Patients with atrial fibrillation (AF) who initiated vitamin K antagonist (VKA) were at highest risk of stroke and bleeding in the first few months of therapy. Understanding of the temporal trend of clinical events in AF patients on non-VKA oral anticoagulant (NOAC) therapy should aid therapeutic decisions.
Purpose
To evaluate the temporal trend of clinical events in AF patients receiving edoxaban in routine clinical practice in the Global ETNA-AF program.
Methods
Global ETNA-AF is a multicentre, prospective, noninterventional program evaluating the safety and effectiveness of edoxaban in patients from European and Asian countries. Thromboembolic, bleeding and death events were analysed separately for the 1st and 2nd year of the follow-up period, using a time-to-first-event estimation of cumulative incidence and annual rate via Kaplan-Meier method.
Results
A total of 27,617 patients were included in this analysis, 48.6% from Europe and 51.4% from Japan, Korea, and Taiwan. Baseline characteristics were consistent with typical AF population in real world studies (Table 1). Approximately 83% of patients received the recommended edoxaban dose. Annualized rates of ischaemic stroke and major bleeding (ISTH) were lower in the 2nd year than in the 1st year: ischaemic stroke 0.59% (95% CI, 0.50–0.70) vs 0.86% (95% CI, 0.75–0.98), p=0.015; major bleeding 0.87% (95% CI, 0.75–1.00) vs 1.15% (95% CI, 1.02–1.29), p=0.036. The trend toward lower rates of ischaemic stroke and major bleeding in the 2nd year was consistent across regions. All-cause mortality increased slightly from the 1st year to the 2nd year, which was not statistically significant and was not driven by cardiovascular (CV) mortality (Table 2).
Conclusion
In routine clinical practice in the Global ETNA-AF program, major bleeding and ischaemic stroke rates in >27,000 patients on edoxaban therapy declined from 1st year to 2nd year. Further analyses will investigate whether such trend is influenced by selection for healthier patients over time. Longer follow-up is needed to better understand long-term trends.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Table 1. Baseline characteristicsTable 2. Annualised clinical event rates
Collapse
Affiliation(s)
- L Dinshaw
- University Heart Center Hamburg, Hamburg, Germany
| | - C Chen
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| | | | - W Jiang
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| | - Y.-H Kim
- Korea University, Seoul, Korea (Republic of)
| | - Y Koretsune
- National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - D Morrone
- University Hospital of Pisa, Pisa, Italy
| | - L Pecen
- Institute of Computer Science of the Czech Academy of Science, Prague, Czechia
| | - P.-E Reimitz
- Daiichi Sankyo Europe GmbH, Clinical Operations and Biostatistics and Data Operations, Munich, Germany
| | - C.-C Wang
- Chang Gung University and Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - T Yamashita
- National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - M Unverdorben
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
78
|
Zhang S, Niu D, Wang D, Nie Y, Song N, Wang J, Ruan X, Huang M, Wada R, Ren J, Ding Y, Zhang K, Tang X, Han R, Liu B, Lu L, Jiang W. Measurement of leakage neutron spectra for aluminium with D-T fusion neutrons and validation of evaluated nuclear data. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
79
|
Bi N, Hu X, Zhao K, Yang Y, Zhang L, E M, Cao J, Ge H, Zhu X, Zhao L, Di Y, Jiang W, Ran J, Zhang H, Zhang T, Shen W, Deng C, Hu C, Chen M, Wang L. P64.04 Hypo-Fractionated Versus Conventionally Fractionated Radiotherapy for Patients with LS-SCLC: An Open-Label, Randomized, Phase 3 Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
80
|
Bi N, Jiang W, Chen M, Fu X, Wang L. P47.18 Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
81
|
Liu YB, Xu BC, Chen YT, Yuan X, Liu JY, Liu T, Du GZ, Jiang W, Yang Y, Zhu Y, Chen LJ, Ding BS, Wei YQ, Yang L. Directed evolution of AAV accounting for long-term and enhanced transduction of cardiovascular endothelial cells in vivo. Mol Ther Methods Clin Dev 2021; 22:148-161. [PMID: 34485601 PMCID: PMC8397840 DOI: 10.1016/j.omtm.2021.05.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 05/28/2021] [Indexed: 02/05/2023]
Abstract
Cardiac endothelial cells (ECs) are important targets for cardiovascular gene therapy. However, the approach of stably transducing ECs in vivo using different vectors, including adeno-associated virus (AAV), remains unexamined. Regarding this unmet need, two AAV libraries from DNA shuffling and random peptide display were simultaneously screened in a transgenic mouse model. Cardiac ECs were isolated by cell sorting for salvage of EC-targeting AAV. Two AAV variants, i.e., EC71 and EC73, enriched in cardiac EC, were further characterized for their tissue tropism. Both of them demonstrated remarkably enhanced transduction of cardiac ECs and reduced infection of liver ECs in comparison to natural AAVs after intravenous injection. Significantly, persistent transgene expression was maintained in mouse cardiac ECs in vivo for at least 4 months. The EC71 vector was selected for delivery of the endothelial nitric oxide synthase (eNOS) gene into cardiac ECs in a mouse model of myocardial infarction. Enhanced eNOS activity was observed in the mouse heart and lung, which was correlated with partially improved cardiac function. Taken together, two AAV capsids were evolved with more efficient transduction in cardiovascular endothelium in vivo, but their endothelial tropism might need to be further optimized for practical application to cardiac gene therapy.
Collapse
Affiliation(s)
- Y B Liu
- Department of Cardiology and Laboratory of Gene Therapy for Heart Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China
| | - B C Xu
- Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Y T Chen
- Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China
| | - X Yuan
- Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - J Y Liu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China
| | - T Liu
- Department of Anesthesiology, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - G Z Du
- Department of Anesthesiology, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - W Jiang
- Molecular Medicine Research Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Y Yang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China
| | - Y Zhu
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - L J Chen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China
| | - B S Ding
- Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China
| | - Y Q Wei
- Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - L Yang
- Department of Cardiology and Laboratory of Gene Therapy for Heart Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China
| |
Collapse
|
82
|
Liu S, Zhao L, Xiao X, Jiang W, Ju Z, Tian M, Li H, Lin H. Acetate promotes lipogenesis in adipocytes but not in hepatocytes of chickens. Br Poult Sci 2021; 63:54-61. [PMID: 34309437 DOI: 10.1080/00071668.2021.1960950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
1.The role of acetate in lipogenesis of chickens remains largely unknown. This trial investigated the effect of sodium acetate (SA) on chicken fat metabolism via in vivo and in vitro experiments.2.The results indicated that supplementation of SA (1.0 g/kg feed) showed marginal to moderate stimulation on the area of the abdominal fat cells and triglyceride (TG) content in liver and adipose tissues. It increased the transcription of some genes involved in fat synthesis and deposition, but did not affect free fatty acid receptor 2 (FFAR2) expression in either liver or abdominal fat.3. In cultured hepatocytes treated with 0.01 mM to 5 mM SA, although mRNA levels of ACC1, PPAR, SREBP-1 c, and FFAR2 were upregulated with SA at certain concentrations, TG content and protein expression of lipogenic genes and FFAR2 were not altered at any dosages. In adipogenic differentiation of preadipocytes, high concentrations of SA (5 mM) exhibited significant increments in TG content and accumulated fat droplets, associated with stimulated transcription of FAS, LPL, AD, FABP4, and FFAR2, as well as elevated protein expression of FABP4 and FFAR2.4. The results showed that adipocytes were more sensitive to acetate than hepatocytes in chickens. While acetate played a minor role in hepatic fat metabolism, it promoted lipogenesis in adipocytes via FFAR2 with the involvement of FAS, LPL, and FABP4.
Collapse
Affiliation(s)
- S Liu
- College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Tai'an, China
| | - L Zhao
- College of Life Sciences, Shandong Agricultural University, Tai'an, China
| | - X Xiao
- College of Life Sciences, Shandong Agricultural University, Tai'an, China
| | - W Jiang
- College of Life Sciences, Shandong Agricultural University, Tai'an, China
| | - Z Ju
- College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Tai'an, China
| | - M Tian
- College of Life Sciences, Shandong Agricultural University, Tai'an, China
| | - H Li
- College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Tai'an, China
| | - H Lin
- College of Life Sciences, Shandong Agricultural University, Tai'an, China
| |
Collapse
|
83
|
Wang JS, Ritterbusch F, Dong XZ, Gao C, Li H, Jiang W, Liu SY, Lu ZT, Wang WH, Yang GM, Zhang YS, Zhang ZY. Optical Excitation and Trapping of ^{81}Kr. Phys Rev Lett 2021; 127:023201. [PMID: 34296902 DOI: 10.1103/physrevlett.127.023201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 06/01/2021] [Indexed: 06/13/2023]
Abstract
We have realized optical excitation, trapping, and detection of the radioisotope ^{81}Kr with an isotopic abundance of 0.9 ppt. The 124 nm light needed for the production of metastable atoms is generated by a resonant discharge lamp. Photon transport through the optically thick krypton gas inside the lamp is simulated and optimized to enhance both brightness and resonance. We achieve a state-of-the-art ^{81}Kr loading rate of 1800 atoms/h, which can be further scaled up by adding more lamps. The all-optical approach overcomes the limitations on precision and sample size of radiokrypton dating, enabling new applications in the earth sciences, particularly for dating of polar ice cores.
Collapse
Affiliation(s)
- J S Wang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - F Ritterbusch
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - X-Z Dong
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - C Gao
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - H Li
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - W Jiang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - S-Y Liu
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - Z-T Lu
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - W-H Wang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - G-M Yang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - Y-S Zhang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| | - Z-Y Zhang
- Hefei National Laboratory for Physical Sciences at the Microscale, CAS Center for Excellence in Quantum Information and Quantum Physics, University of Science and Technology of China, 96 Jinzhai Road, Hefei 230026, China
| |
Collapse
|
84
|
Wang Q, Xiao B, Jiang W, Steele S, Cai J, Pan Z, Zhang X, Ding P. P-187 Watch-and-wait strategy for DNA mismatch repair-deficient/microsatellite instability-high rectal cancer with a clinical complete response after neoadjuvant immunotherapy: An observational cohort study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
85
|
Guo HJ, Ding X, Jiang W, Jiang J, Wu Y, Shu Z, Li GW, Hu YH, Yin DP. [Association analysis of famine exposure during early life and risk of hypertension in adulthood]. Zhonghua Yu Fang Yi Xue Za Zhi 2021; 55:732-736. [PMID: 34139812 DOI: 10.3760/cma.j.cn112150-20210111-00025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the relationship between exposure to famine in early life and the risk of hypertension in adulthood. Methods: The medical data of Yichang Health Management Big Data Center from 2018 to 2019 were analyzed. A retrospective cohort study design was adopted, with hypertension as the study outcome, and different life periods exposed to the Great Famine in China were divided into groups. Multivariate logistic regression model was used to analyze the relationship between famine exposure in early life and hypertension in adulthood. At the same time, the interaction between gender and famine exposure was analyzed. Results: The age of 142 016 subjects was (60. 56±4.43). Among them, men accounted for 46.36% (65 845/142 016) and women accounted for 53.64% (76 171/142 016). There are 42 575(29.98%), 19 644(13.83%), 28 405(20.00%), 28 305(19.93%), 23 087 (19.93%) in non-famine exposure group, fetal famine exposure group, early childhood famine exposure group and late childhood famine exposure group, respectively. The prevalence of hypertension was 17.57% (24 947 cases). Multivariate logistic regression model analysis showed that after adjusting for related confounding factors, compared with non-famine exposure group, the risk of hypertension in fetal, early childhood, middle childhood and late childhood famine exposure group was higher and the OR (95%CI) values were 1.16 (1.11-1.22), 1.27 (1.21-1.33), 1.54 (1.47-1.60) and 1.84 (1.76-1.92), respectively. There was an interaction between sex and famine exposure group (P<0.001). The above association is stronger among women than among men. Conclusion: Famine exposure in early life may increase the risk of hypertension in adulthood, and the risk of women is greater than that of men.
Collapse
Affiliation(s)
- H J Guo
- Department of Cardiology, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing 101300, China
| | - X Ding
- School of Public Health, North China University of Science and Technology, Tangshan 063210, China
| | - W Jiang
- Department of National Immunization Program, Yichang Center for Disease Control and Prevention, Yichang 443003, China
| | - J Jiang
- Department of National Immunization Program, Yichang Center for Disease Control and Prevention, Yichang 443003, China
| | - Y Wu
- School of Public Health, North China University of Science and Technology, Tangshan 063210, China
| | - Z Shu
- School of Public Health, North China University of Science and Technology, Tangshan 063210, China
| | - G W Li
- Department of National Immunization Program, Yichang Center for Disease Control and Prevention, Yichang 443003, China
| | - Y H Hu
- Epidemiology Office, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - D P Yin
- Epidemiology Office, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| |
Collapse
|
86
|
Morrone D, Unverdorben M, Chen C, Dinshaw L, Jiang W, Kim YH, Kirchhof P, Koretsune Y, Pecen L, Reimitz PE, Wang CC, Yamashita T, De Caterina R. Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF. Europace 2021. [DOI: 10.1093/europace/euab116.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo
Background
Age is a risk factor for ischemic stroke and bleeding in patients with atrial fibrillation (AF). The large dataset from the global prospective, noninterventional ETNA-AF program allows for analysis of the impact of age on clinical events in AF patients treated with edoxaban.
Purpose
Evaluate the safety and effectiveness of edoxaban by age subgroups and the impact of age on clinical events.
Methods
Baseline patient characteristics, thromboembolic and bleeding events, and mortality data were collected from patients with 2-year follow-up in ETNA-AF program and analyzed in defined age subgroups. Cox regression analysis was conducted using age as a continuous variable and clinical events as outcome variables.
Results
A total of 27,617 patients were categorized into four age subgroups: <65, 65-74, 75-84 and ≥85 years. Patient demographics and baseline characteristics are shown in the Table. Percentage of male, mean body weight, and mean creatinine clearance decreased with age, whereas percentages of patients with heart failure, patients on reduced dose edoxaban 30 mg, mean stroke and bleeding risk scores increased with age. The annualized rates of ischemic stroke and major bleeding increased with age, yet remained low. Importantly, the rate of intracranial hemorrhage was low across age groups, including the ≥85 years group. The hazard ratio (HR) for ischemic stroke was 1.041 (95%CI 1.028-1.053), ie. with a 1-year increase in age, the risk of ischemic stroke increased by 4.1%. The HRs for other clinical events were: major bleeding 1.044 (95%CI 1.033-1.055), intracranial hemorrhage 1.027 (95%CI 1.007-1.046), major gastrointestinal bleeding 1.065 (95%CI 1.048-1.081), all-cause mortality 1.086 (95%CI 1.079-1.093).
Conclusion
Two-year follow-up data from the global ETNA-AF program support the use of edoxaban as a safe and effective treatment for AF patients across all age groups, including the very elderly, in routine clinical care. The impact of age on the risk of ICH was smaller than that of ischemic stroke and major bleeding. <65 yr(N = 4,278) ≥65-74 yr(N = 9,396) ≥75-84 yr(N = 10,728) ≥85 yr(N = 3,214) Age [years], mean (SD)Male, %Weight [kg], mean (SD) 57.3 (6.6)72.580.6 (20.3) 69.9 (2.9)61.973.0 (17.7) 79.1 (2.8)53.968.0 (16.0) 87.9 (2.8)42.260.1 (14.9) CrCL [mL/min], mean (SD)CHA2DS2-VASc, mean (SD)Mod. HAS-BLED≠, mean (SD) 101.8 (33.7)1.6 (1.1)1.4 (1.0) 75.3 (22.3)2.8 (1.2)2.5 (1.1) 57.9 (18.1)4.1 (1.2)2.7 (1.0) 42.5 (14.3)4.4 (1.3)2.7 (1.0) 2-year clinical events Major Bleeding (ISTH)%/yr [95% CI] Intracranial Hemorrhage%/yr [95% CI] Major GI Bleeding%/yr [95% CI] 0.49 [0.35; 0.68] 0.18 [0.09; 0.30] 0.22 [0.13; 0.36] 0.84 [0.70; 0.99] 0.26 [0.18; 0.34] 0.34 [0.26; 0.44] 1.16 [1.00; 1.32] 0.31 [0.23; 0.40]0.60 [0.49; 0.72] 1.88 [1.51; 2.30] 0.46 [0.29; 0.69]1.19 [0.90; 1.53] Any Stroke%/yr [95% CI]Ischemic Stroke%/yr [95% CI]Hemorrhagic Stroke%/yr [95% CI] 0.54 [0.38; 0.73]0.38[0.26; 0.56]0.12[0.06; 0.23] 0.79 [0.66; 0.94]0.59[0.47; 0.71]0.19[0.13; 0.27] 1.15 [1.00; 1.32]0.89[0.76; 1.04]0.23[0.16; 0.31] 1.53 [1.21; 1.92]1.21[0.92; 1.56]0.320.18; 0.52] All-cause Death%/yr [95% CI]CV Death (sensitivity)%/yr [95% CI] 1.05 [0.83; 1.32]0.51[0.36; 0.70] 1.82 [1.62; 2.04]0.83[0.69; 0.98 3.51 [3.25; 3.80]1.65[1.47; 1.84] 9.08 [8.27; 9.96]4.16[3.62; 4.77] ≠Excluding labile INR.
Collapse
Affiliation(s)
- D Morrone
- University Hospital of Pisa, Pisa, Italy
| | - M Unverdorben
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - C Chen
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - L Dinshaw
- University Heart Center Hamburg, Hamburg, Germany
| | - W Jiang
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - Y-H Kim
- Korea University, Seoul, Korea (Republic of)
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - Y Koretsune
- National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - L Pecen
- Institute of Computer Science of the Czech Academy of Science, Prague, Czechia
| | - P-E Reimitz
- Daiichi Sankyo Europe, GmbH, Munich, Germany
| | - C-C Wang
- Chang Gung University and Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - T Yamashita
- National Hospital Organization Osaka National Hospital, Osaka, Japan
| | | |
Collapse
|
87
|
Vanassche T, Colonna P, Santamaria A, Chen C, Von Heymann C, Jin J, Saxena M, Jiang W, Unverdorben M. Periprocedural anticoagulation management in edxoaban patients undergoing catheter-based cardiovascular procedures: analyses of the noninterventional global EMIT study. Europace 2021. [DOI: 10.1093/europace/euab116.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo
Background
The optimal periprocedural management of direct oral anticoagulants (DOAC), including edoxaban, in patients undergoing catheter-based cardiovascular procedures is unknown, and mainly based on physician opinion and experience.
Purpose
To assess real-world management of edoxaban in patients undergoing cardiovascular procedures, and to report their clinical events.
Methods
Global EMIT-AF/VTE is a prospective study of periprocedural management in edoxaban-treated patients undergoing diagnostic and therapeutic procedures. We report the data from patients undergoing cardiovascular procedures. Timing and duration of edoxaban interruption were at the treating physician’s discretion. Outcomes were collected from 5 days before until 30 days post procedure. Primary outcome was the incidence of major bleeding (MB); secondary outcomes included incidence of clinically relevant non-major bleeding (CRNMB) and acute thromboembolic events (ATE).
Results
Data was collected from 301 and 311 procedures with arterial or venous access, respectively. Baseline characteristics are shown in Table 1. Edoxaban was not interrupted in 36.9% of arterial and 52.7% of venous procedures. Edoxaban was interrupted pre-procedure in 41% of arterial and 32.8% of venous procedures. The median periprocedural interruption was 2 days. The overall incidence of bleeding was very low. Any bleeding was reported in 8 patients undergoing arterial and 10 patients undergoing venous procedures (2.7% and 3.2%). MB or CRNMB occurred in 2 arterial and 3 venous procedures (0.7% and 1.0%) and ATE occurred in 5 arterial and 1 venous procedure (1.7% and 0.3%, Table 1).
Conclusions
In this study, the periprocedural risks of bleeding and thrombotic events were low. About a third of arterial access procedures and half of venous access procedures were performed without edoxaban interruption. Arterial(n = 301) Venous(n = 311) Baseline characteristics Age, year, mean (SD)Male, n (%)Weight (kg), mean (SD) 71.9 (8.5)211 (70.1%)80.8 (16.7) 64.6 (11.1)215 (69.1%)84.1 (17.4) CrCL (mL/min), mean (SD) CHA2DS2-VASc score, mean (SD)HAS-BLED score, mean (SD) 73.5 (29.8) 3.3 (1.5)2.0 (1.0) 88.9 (35.5) 2.2 (1.5)1.3 (1.0) Edoxaban 60 mg / 30 mg, % 73% / 26% 88% / 26% Coronary heart disease, n (%) Congestive heart failure, n (%) 101 (33.6%) 58 (19.3%) 51 (16.4%) 33 (10.6%) Interruption of edoxaban, n (%) No interruption Pre-procedure only Post-procedure only Pre- and post-procedure 111 (36.9%)125 (41.5%)12 (4.0%)53 (17.6%) 164 (52.7%)102 (32.8%)8 (2.6%)37 (11.9%) Clinical events, n (%) MB or CRNMBACSStroke/Transient ischemic attackCV mortalityAll-cause mortality 2 (0.7%)2 (0.7%)3 (1.0%)1 (0.3%)2 (0.7%) 3 (1.0%) 01 (0.3%)00
Collapse
Affiliation(s)
- T Vanassche
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - P Colonna
- Polyclinic Hospital of Bari, Bari, Italy
| | - A Santamaria
- University Hospital Vilaopo y Torrevieja, Alicante, Spain
| | - C Chen
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - C Von Heymann
- Vivantes Klinikum im Friedrichshain, Berlin, Germany
| | - J Jin
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - M Saxena
- William Harvey Research Institute, London, United Kingdom of Great Britain & Northern Ireland
| | - W Jiang
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - M Unverdorben
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| |
Collapse
|
88
|
Dinshaw L, Unverdorben M, Chen C, De Caterina R, Jiang W, Kim YH, Koretsune Y, Morrone D, Pecen L, Reimitz PE, Wang CC, Yamashita T, Kirchhof P. Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program. Europace 2021. [DOI: 10.1093/europace/euab116.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo
Background and Purpose
The large global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program was designed to assess the safety and effectiveness of edoxaban, complementing randomized clinical trials.
Methods
ETNA collects data on patient characteristics and clinical events in unselected AF patients treated with edoxaban for stroke prevention, integrating data from prospective, noninterventional studies conducted in Europe, Japan, South Korea, and Taiwan.
Results
The 2-year follow-up analysis included 27,617 patients, the majority of whom (82.6%) received the recommended dose according to the local label. At baseline, the mean age was 73.6 ± 9.8 years and 58.1% were male. Half of the patients (50.5%) were 75 years or older. The CHA2DS2-VASc score was 3.3 ± 1.5, and the modified HAS-BLED score was 2.4 ± 1.1. The rate of ischemic stroke was 0.74%/yr, major bleeding 1.02%/yr, intracranial hemorrhage 0.29%/yr, and major gastrointestinal (GI) bleeding 0.51%/yr. All-cause mortality was 3.13%/yr, and cardiovascular (CV) mortality 1.45%/yr (see Table).
Conclusion
The rates of ischemic stroke and major bleeding events remained low globally and across regions during the two-year follow-up period in AF patients treated with edoxaban. Global(N = 27,617) Japan(N = 11,330) Korea/Taiwan(N = 2,870) Europe(N = 13,417) Age, mean (SD) 73.6 (9.8) 74.2 (10.1) 71.6 (9.5) 73.6 (9.5) Gender, male, % 58.1 59.4 60.2 56.6 Weight [kg], median (IQR) 69 (58, 81) 59 (51, 68) 65 (57, 73) 80 (70, 90) CrCL [mL/min], mean (SD) 68.7 (28.4) 63.9 (25.8) 63.4 (23.7) 74.4 (30.5) CHA2DS2-VASc, mean (SD) 3.3 (1.5) 3.5 (1.7) 3.1 (1.4) 3.2 (1.4) Mod. HAS-BLED≠, mean (SD) 2.4 (1.1) 2.4 (1.1) 2.3 (1.1) 2.5 (1.1) Edoxaban 60mg/30mg, % 53.5 / 46.5 27.6 / 72.4 48.8 / 51.2 76.4 / 23.6 2-year clinical events, N (%/year), [95% CI] Major Bleeding (ISTH) 477 (1.02) [0.93; 1.11] 188 (1.09) [0.94; 1.25] 51 (1.00) [0.74; 1.31] 238 (0.97) [0.85; 1.11] Intracranial Hemorrhage 135 (0.29) [0.24; 0.34] 68 (0.39) [0.30; 0.50] 17 (0.33) [0.19; 0.53] 50 (0.20) [0.15; 0.27] Major GI Bleeding 241 (0.51) [0.45; 0.58] 122 (0.70) [0.58; 0.84] 18 (0.35) [0.21; 0.55] 101 (0.41) [0.33; 0.50] Any Stroke 455 (0.97) [0.88; 1.06] 244 (1.41) [1.24; 1.60] 54 (1.06) [0.80; 1.38] 157 (0.64) [0.54; 0.75] Ischemic Stroke 347 (0.74) [0.66; 0.82] 179 (1.03) [0.89; 1.20] 43 (0.84) [0.61; 1.13] 125 (0.51) [0.42; 0.61] Hemorrhagic Stroke 99 (0.21) [0.17; 0.26] 67 (0.39) [0.30; 0.49] 9 (0.17) [0.08; 0.33] 23 (0.09) [0.06; 0.14] All-cause Death 1479 (3.13) [2.98; 3.30] 470 (2.70) [2.46; 2.96] 72 (1.40) [1.09; 1.76] 937 (3.80) [3.56; 4.05] CV Death 684 (1.45) [1.34; 1.56] 140 (0.80) [0.68; 0.95] 26 (0.50) [0.33; 0.74] 518 (2.10) [1.92; 2.29] ≠Excluding labile INR.
Collapse
Affiliation(s)
- L Dinshaw
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - M Unverdorben
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - C Chen
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | | | - W Jiang
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - Y-H Kim
- Korea University, Seoul, Korea (Republic of)
| | - Y Koretsune
- National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - D Morrone
- University Hospital of Pisa, Pisa, Italy
| | - L Pecen
- Institute of Computer Science of the Czech Academy of Science, Prague, Czechia
| | - P-E Reimitz
- Daiichi Sankyo Europe, GmbH, Munich, Germany
| | - C-C Wang
- Chang Gung University and Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | | | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
89
|
Alemanno F, An Q, Azzarello P, Barbato FCT, Bernardini P, Bi XJ, Cai MS, Catanzani E, Chang J, Chen DY, Chen JL, Chen ZF, Cui MY, Cui TS, Cui YX, Dai HT, D'Amone A, De Benedittis A, De Mitri I, de Palma F, Deliyergiyev M, Di Santo M, Dong TK, Dong ZX, Donvito G, Droz D, Duan JL, Duan KK, D'Urso D, Fan RR, Fan YZ, Fang K, Fang F, Feng CQ, Feng L, Fusco P, Gao M, Gargano F, Gong K, Gong YZ, Guo DY, Guo JH, Guo XL, Han SX, Hu YM, Huang GS, Huang XY, Huang YY, Ionica M, Jiang W, Kong J, Kotenko A, Kyratzis D, Lei SJ, Li S, Li WL, Li X, Li XQ, Liang YM, Liu CM, Liu H, Liu J, Liu SB, Liu WQ, Liu Y, Loparco F, Luo CN, Ma M, Ma PX, Ma T, Ma XY, Marsella G, Mazziotta MN, Mo D, Niu XY, Pan X, Parenti A, Peng WX, Peng XY, Perrina C, Qiao R, Rao JN, Ruina A, Salinas MM, Shang GZ, Shen WH, Shen ZQ, Shen ZT, Silveri L, Song JX, Stolpovskiy M, Su H, Su M, Sun ZY, Surdo A, Teng XJ, Tykhonov A, Wang H, Wang JZ, Wang LG, Wang S, Wang XL, Wang Y, Wang YF, Wang YZ, Wang ZM, Wei DM, Wei JJ, Wei YF, Wen SC, Wu D, Wu J, Wu LB, Wu SS, Wu X, Xia ZQ, Xu HT, Xu ZH, Xu ZL, Xu ZZ, Xue GF, Yang HB, Yang P, Yang YQ, Yao HJ, Yu YH, Yuan GW, Yuan Q, Yue C, Zang JJ, Zhang F, Zhang SX, Zhang WZ, Zhang Y, Zhang YJ, Zhang YL, Zhang YP, Zhang YQ, Zhang Z, Zhang ZY, Zhao C, Zhao HY, Zhao XF, Zhou CY, Zhu Y. Measurement of the Cosmic Ray Helium Energy Spectrum from 70 GeV to 80 TeV with the DAMPE Space Mission. Phys Rev Lett 2021; 126:201102. [PMID: 34110215 DOI: 10.1103/physrevlett.126.201102] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 03/25/2021] [Accepted: 04/06/2021] [Indexed: 06/12/2023]
Abstract
The measurement of the energy spectrum of cosmic ray helium nuclei from 70 GeV to 80 TeV using 4.5 years of data recorded by the Dark Matter Particle Explorer (DAMPE) is reported in this work. A hardening of the spectrum is observed at an energy of about 1.3 TeV, similar to previous observations. In addition, a spectral softening at about 34 TeV is revealed for the first time with large statistics and well controlled systematic uncertainties, with an overall significance of 4.3σ. The DAMPE spectral measurements of both cosmic protons and helium nuclei suggest a particle charge dependent softening energy, although with current uncertainties a dependence on the number of nucleons cannot be ruled out.
Collapse
Affiliation(s)
- F Alemanno
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - Q An
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - P Azzarello
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - F C T Barbato
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - P Bernardini
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - X J Bi
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
| | - M S Cai
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - E Catanzani
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Perugia, I-06123 Perugia, Italy
| | - J Chang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - D Y Chen
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - J L Chen
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Z F Chen
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - M Y Cui
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - T S Cui
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y X Cui
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - H T Dai
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - A D'Amone
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - A De Benedittis
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - I De Mitri
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - F de Palma
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - M Deliyergiyev
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - M Di Santo
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - T K Dong
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z X Dong
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - G Donvito
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
| | - D Droz
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - J L Duan
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - K K Duan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - D D'Urso
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Perugia, I-06123 Perugia, Italy
| | - R R Fan
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - Y Z Fan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - K Fang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - F Fang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - C Q Feng
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - L Feng
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - P Fusco
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
- Dipartimento di Fisica "M. Merlin" dell'Università e del Politecnico di Bari, I-70126 Bari, Italy
| | - M Gao
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - F Gargano
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
| | - K Gong
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - Y Z Gong
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - D Y Guo
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J H Guo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - X L Guo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - S X Han
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y M Hu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - G S Huang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - X Y Huang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - Y Y Huang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - M Ionica
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Perugia, I-06123 Perugia, Italy
| | - W Jiang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - J Kong
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - A Kotenko
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - D Kyratzis
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - S J Lei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - S Li
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - W L Li
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - X Li
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - X Q Li
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y M Liang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - C M Liu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - H Liu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - J Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - S B Liu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - W Q Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y Liu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - F Loparco
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
- Dipartimento di Fisica "M. Merlin" dell'Università e del Politecnico di Bari, I-70126 Bari, Italy
| | - C N Luo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - M Ma
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - P X Ma
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - T Ma
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - X Y Ma
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - G Marsella
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - M N Mazziotta
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
| | - D Mo
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X Y Niu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X Pan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - A Parenti
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - W X Peng
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - X Y Peng
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - C Perrina
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - R Qiao
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J N Rao
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - A Ruina
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - M M Salinas
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - G Z Shang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - W H Shen
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Z Q Shen
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z T Shen
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - L Silveri
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - J X Song
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - M Stolpovskiy
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - H Su
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - M Su
- Department of Physics and Laboratory for Space Research, the University of Hong Kong, Pok Fu Lam, Hong Kong SAR 999077, China
| | - Z Y Sun
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - A Surdo
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - X J Teng
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - A Tykhonov
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - H Wang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - J Z Wang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - L G Wang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - S Wang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - X L Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y F Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y Z Wang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z M Wang
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - D M Wei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - J J Wei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Y F Wei
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - S C Wen
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - D Wu
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J Wu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - L B Wu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - S S Wu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - X Wu
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - Z Q Xia
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - H T Xu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Z H Xu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - Z L Xu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z Z Xu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - G F Xue
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - H B Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - P Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y Q Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - H J Yao
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y H Yu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - G W Yuan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - Q Yuan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - C Yue
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - J J Zang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - F Zhang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - S X Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - W Z Zhang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Y J Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y L Zhang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y P Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y Q Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z Y Zhang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - C Zhao
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - H Y Zhao
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X F Zhao
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - C Y Zhou
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y Zhu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| |
Collapse
|
90
|
Yu CL, Xu NW, Jiang W, Zhang H, Ma Y. LncRNA DSCAM-AS1 promoted cell proliferation and invasion in osteosarcoma by sponging miR-101. Eur Rev Med Pharmacol Sci 2021; 24:7709-7717. [PMID: 32744697 DOI: 10.26355/eurrev_202007_22274] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Long noncoding RNAs (lncRNAs) play critical roles in osteosarcoma (OS) progression. LncRNA DSCAM-AS1 has been reported to function as a tumor promoter in various cancers. However, the potential mechanism of DSCAM-AS1 in OS remains rarely know. PATIENTS AND METHODS The expression levels of DSCAM-AS1 and miR-101 were detected by RT-qPCR. The correlation between DSCAM-AS1 and miR-101 expression was analyzed by Pearson's correlation. Kaplan-Meier analysis was used to assess the overall survival rate. Cell viability and invasion were assessed by MTT assay and transwell assays, respectively. A Luciferase reporter assay was used to identify the relationship between DSCAM-AS1 and miR-101. RESULTS In the present study, it was demonstrated that DSCAM-AS1 expression was significantly upregulated in OS tissues and cells and high expression of DSCAM-AS1 predicted poor prognosis in OS patients. In addition, the silencing of DSCAM-AS1 suppressed the viability and invasion of OS cells, while DSCAM-AS1 overexpression promoted cell viability and invasion. Furthermore, we found that DSCAM-AS1 inhibited miR-101 expression by direct interaction and DSCAM-AS1 promoted OS progression by sponging miR-101. In addition, miR-101 expression was negatively correlated with DSCAM-AS1 expression. Patients with low miR-101 expression had a shorter overall survival time compared with those with high miR-101 expression. CONCLUSIONS The present study demonstrated that DSCAM-AS1 accelerated OS cell progression by sponging miR-101, which might provide a new sight in the treatment of OS.
Collapse
Affiliation(s)
- C-L Yu
- Department of Spinal Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, P.R. China.
| | | | | | | | | |
Collapse
|
91
|
Li SZ, Jiang W, Li WL, Lu X, Wang GC. [Clinico-pathological and follow-up analysis of 5 skeletal muscle single-organ vasculitis cases]. Zhonghua Yi Xue Za Zhi 2021; 101:803-807. [PMID: 33765722 DOI: 10.3760/cma.j.cn112137-20200630-02000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objectives: To delineate clinico-pathological features, treatment and outcome of skeletal muscle single-organ vasculitis (SM-SOV). Methods: The clinico-pathological characteristic of SM-SOV cases treated over 3 years in China-Japan Friendship Hospital were retrospectively analyzed and the data were compared with the cases from the literature. Results: Five patients (2 women and 3 men) with a median age of 36 years were included in this study. The main clinical manifestations were lower limb myalgia (5/5) and fever (1/5). The most frequent laboratory findings included high erythrocyte sedimentation rate (5/5), high C reactive protein (5/5) and leukocytosis (1/5). No elevated creatine kinase (CK) was found in these cases. Four patients received electromyogram examination and none of them showed myogenic injury. On MRI, hyperintense signals in T2 weighted image (T2WI) and/or short TI inversion recovery (STIR) and normal unenhanced T1 weighted image (T1WI) of one or several leg muscles was founded in all 5 patients. All muscle specimens showed nongranulomatous vasculitis without myonecrosis affecting small sized artery (5/5) in perimysia (75.0%, 3/4) or both perimysia and fascia (25.0%, 1/4). Corticosteroids (5/5) and immunosuppressants (5/5) were the main agents prescribed. With a median follow-up of 24 months, sustained remission was observed in 3 patients, relapses occurred in 2 patients. Conclusion: SM-SOV should be considered for patients with lower limb myalgia, high inflammatory markers and normal/low CK level. The diagnosis of SM-SOV should be applied when there are both histologic evidence of vasculitis and a minimum of 6 months of follow-up surveillance without evidences suggesting extra-muscular involvement. Corticosteroid combined with immunosuppressant is effective.
Collapse
Affiliation(s)
- S Z Li
- Graduate School, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| | - W Jiang
- Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing 100029, China
| | - W L Li
- Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing 100029, China
| | - X Lu
- Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing 100029, China
| | - G C Wang
- Graduate School, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| |
Collapse
|
92
|
Li Miao, Qian S, Qi S, Jiang W, Dong K. Culture Medium Optimization and Active Compounds Investigation of an Anti-Quorum Sensing Marine Actinobacterium Nocardiopsis dassonvillei JS106. Microbiology (Reading) 2021. [DOI: 10.1134/s0026261721010070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
93
|
Shen B, Yu X, Jiang W, Yuan H, Zhao M, Zhou H, Pan Z. Green Conversion of Saponins to Diosgenin in an Alcoholysis System Catalyzed by Solid Acid Derived from Phosphorus Tailings. ACS Omega 2021; 6:5423-5435. [PMID: 33681582 PMCID: PMC7931428 DOI: 10.1021/acsomega.0c05627] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 02/10/2021] [Indexed: 05/02/2023]
Abstract
This work proposed to prepare solid acid from phosphorus tailings and successfully convert Dioscorea zingiberensis C.H. Wright (DZW) into diosgenin from the perspective of solid waste resource reuse and clean production. The results showed that SiO2-SO3H solid acid could catalyze the production of diosgenin from total saponins under solvothermal reaction conditions. In addition, the parameters of a single factor, such as the amount of SiO2-SO3H, solvent volume, reaction temperature, and reaction time, were optimized to confirm the optimal range of reaction conditions, and the optimal process conditions were determined by the response surface method. The yield of diosgenin was 2.45 ± 0.17% under the optimum conditions, and the yield of diosgenin was increased by 12.90% compared with the traditional acid hydrolysis process. Except the relatively higher catalytic activity, the alcoholysis approach for the production of diosgenin has no waste liquid to discharge. The products were analyzed by high-performance liquid chromatography-mass spectrometry, and the pathway to convert total saponins into diosgenin under SiO2-SO3H has been proposed. Moreover, the adopted catalyst can be prepared with very low cost from phosphorus tailings. Considering the obvious superiorities, the alcoholysis approach in this work could be a promising strategy for green production of diosgenin as well as a possible utilization pathway of phosphorus tailings.
Collapse
Affiliation(s)
- Bowei Shen
- College
of Chemistry and Environmental Technology, Wuhan Institute of Technology, Wuhan 430073, China
| | - XueJun Yu
- Three
Gorges Public Inspection and Testing Center, Hubei 430071, China
| | - Wenxiu Jiang
- College
of Chemistry and Environmental Technology, Wuhan Institute of Technology, Wuhan 430073, China
| | - Hui Yuan
- College
of Chemistry and Environmental Technology, Wuhan Institute of Technology, Wuhan 430073, China
| | - Mengqi Zhao
- College
of Chemistry and Environmental Technology, Wuhan Institute of Technology, Wuhan 430073, China
| | - Hong Zhou
- College
of Chemistry and Environmental Technology, Wuhan Institute of Technology, Wuhan 430073, China
| | - Zhiquan Pan
- College
of Chemistry and Environmental Technology, Wuhan Institute of Technology, Wuhan 430073, China
- Three
Gorges Public Inspection and Testing Center, Hubei 430071, China
| |
Collapse
|
94
|
Jiang W, Sun W, Li W, Gao J, Wang H, Zhou W, Liang J, Zhao C, Wang L. P09.01 Different Administration Routes of Endostar Combined with Chemotherapy in the Treatment of Advanced NSCLC, a Real World Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
95
|
Huang M, Chen SP, Dai YY, Yang Y, Jiang W, Wang F, Zhang JX, Zhu QX. [Cathepsin L mediates glomerular endothelial cell injury by cleavaging complement C3 in trichloroethylene-sensitized mice]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2021; 39:5-11. [PMID: 33535331 DOI: 10.3760/cma.j.cn121094-20200701-00380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To observe the expressions of complement 3 (C3) and endothelial cell injury-associated proteins before and after cathepsin L (CTSL) blockade in renal injury of trichloroethylene (TCE) -sensitized mice. Methods: In June 2018, 41 SPF female BALB/c mice were divided respectively into blank control group (n=5) , vehicle control group (n=5) , TCE group (n=15) and TCE+CTSLi group (n=16) to establish trichloroethylene-sensitized mice model by pretreating the mice with intraperitoneal injection of CTSL inhibitor (CTSLi) and using TCE for the first and last challenge. According to the skin sensitization score, the mice were divided into positive group and negative group. 72 hours after the last challenge, the renal function indexes of the mice were detected, the pathological changes of mice kidneys were observed, and the glomerular C3 and endothelial cell damage-related proteins [vascular cell adhesion molecule 1 (VCAM-1) , tight junction protein 5 (Claudin-5) and Syndecan-1] expression levels were detected. Results: The sensitization rates of mice in TCE group and TCE+CTSLi group were 53.3% (8/15) and 50.0% (8/16) , respectively, and there was no significant difference between the two groups (P>0.05) . Compared with vehicle control group and the corresponding TCE negative group, the serum creatinine (CRE) and blood urea nitrogen (BUN) levels of mice in the TCE positive group was increased, while the TCE positive group were higher than the TCE+CTSLi positive group (P<0.05) . Pathological examination showed obvious vacuolar degeneration and cellular edema in the mice kidney of the TCE positive group. In the TCE+CTSLi positive group, the above pathological damage was significantly improved. Immunohistochemical results showed that the expression of glomerular C3 fragment and VCAM-1 in TCE positive group were significantly higher than that of the vehicle control and TCE negative group (P<0.05) , while TCE+CTSLi positive group was significantly lower than that of TCE positive group (P<0.05) . Western blot test results showed that the relative expression levels of Claudin-5 and Syndecan-1 protein in the mice glomeruli of TCE positive group were significantly lower than those in the vehicle control group and TCE negative group (P<0.05) . Compared with the TCE positive group, the Claudin-5 protein was increased in the kidney of the TCE+CTSLi positive group, but the difference was not statistically significant (P>0.05) , while the Syndecan-1 protein was significantly increased in the TCE+CTSLi positive group (P<0.05) . Conclusion: CTSL may mediate the glomerular structural damage by cutting complement C3, activating the complement system, damaging endothelial cell structural protein Syndecan-1 and overexpressing adhesion molecule VCAM-1 in TCE-sensitized mice. Inhibiting the expression of CTSL may be an effective way to protect the glomerular integrity of structure and function in pharmacology.
Collapse
Affiliation(s)
- M Huang
- Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Hefei 230032, China
| | - S P Chen
- Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Hefei 230032, China
| | - Y Y Dai
- Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Hefei 230032, China
| | - Y Yang
- Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Hefei 230032, China
| | - W Jiang
- Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Hefei 230032, China
| | - F Wang
- Department of Dermatology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
| | - J X Zhang
- Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Hefei 230032, China
| | - Q X Zhu
- Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Hefei 230032, China; Institute of Dermatology, the First Affiliated Hospital of Anhui Medical University, Hefei 230032, China
| |
Collapse
|
96
|
Qu XL, Yang YL, Liu SX, Shi YP, Lin BC, Sun BB, Zhong X, Yang CZ, Jiang W. [Post-discharge growth of extremely premature infants within corrected age of 24 months]. Zhonghua Er Ke Za Zhi 2021; 58:982-988. [PMID: 33256320 DOI: 10.3760/cma.j.cn112140-20200628-00670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To demonstrate the post-discharge catch-up growth of extremely premature infants (EPI) within 24 months of corrected age. Methods: This study retrospectively collected the anthropomorphic measurements of 311 EPI who visited Shenzhen Maternity and Child Healthcare Hospital from August 2013 to April 2020. These infants were stratified according to gestational age at birth (GA): 23-24+6weeks, 25-26+6weeks, 27-27+6weeks; and birth weight:<750 g, 750-999 g, ≥1 000 g. The anthropomorphic measurements, including weight, length, and head circumference for age, were recorded timely from discharge to 24 months of corrected age. And the growth curve stratified by GA and birth weight were fitted in both chronological age and corrected age, which were then compared with the World Health Organization Child Growth Standards for term infant (2006 version), to investigate the catch-up growth pattern of EPI. And appropriate catch-up was defined as the measurements reached the 25th percentile of WHO growth curve. Results: In these 311 EPI, 184 were males and 127 females, with gestational age of 23-27+6 weeks and birth weight of 480-1 430 g. Regardless of the GA and birth weight, the growth curves fitted in corrected age failed to overlap with that in chronological age by 24 months of corrected age. The growth velocity of weight, length and head circumference in both corrected and chronological age were all positively correlated with GA and birth weight: the 27-27+6weeks group showed a preferable growth pattern than the 25-26+6weeks group, and the curve of the 23-24+6weeks group was most unfavorable; and the same pattern was observed between the subgroups of different birth weight. Furthermore, the GA had more significant impact on the catch-up growth pattern than birth weight did. When assessed with corrected age curve, the weight and length of both male and female EPIs achieved appropriate catch-up by 24 months, as well as the head circumference of girls; whereas, boys' head circumference reached appropriate catch-up at the corrected age of 9 months, but fell behind the 25th percentile after that. However, when assessed with chronological age curve, both boys and girls failed to achieve appropriate catch-up in weight, length and head circumference by age 24 months. And no matter in corrected or chronological age, all physical measurements of girls were lower than those of boys. Conclusions: The rapid catch-up growth of EPI happens within 6 months of corrected age. The lower the birth weight and gestational age, the lower the physical measurements at each corresponding month of age, and the longer it takes to achieve appropriate catch-up. Gestational age has a greater impact on the longitudinal catch-up growth than birth weight does. And girls generally grow slower than boys in either correct or actual age. Before 24 months of corrected age, the growth should be assessed with corrected age rather than chronological age.
Collapse
Affiliation(s)
- X L Qu
- Department of Child Psychology and Rehabilitation, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - Y L Yang
- Department of Child Psychology and Rehabilitation, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - S X Liu
- Department of Child Psychology and Rehabilitation, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - Y P Shi
- Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - B C Lin
- Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - B B Sun
- Department of Child Psychology and Rehabilitation, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - X Zhong
- Department of Child Psychology and Rehabilitation, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - C Z Yang
- Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| | - W Jiang
- Department of Child Psychology and Rehabilitation, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518017, China
| |
Collapse
|
97
|
Yang S, Jiang W, Bao XQ, Yao W, Chen G, Zhang H, Chen X, Bu Q, Yang SH, Qi YN, Wang WQ, Han YP. [Effect of bone marrow mononuclear cell transplantation on miRNA-21 and miRNA-155 expression in mice with ulcerative colitis]. Zhonghua Yi Xue Za Zhi 2020; 100:3529-3533. [PMID: 33256297 DOI: 10.3760/cma.j.cn112137-20200321-00869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the effect of bone marrow mononuclear cell transplantation on the expression of miRNA-21 and miRNA-155 in mice with ulcerative colitis(UC). Methods: Healthy and clean KM mice aged 6-8 weeks were randomly divided into transplantation group, model group and normal control group with 15 mice in each group. In the transplantation group and model group, dextran sodium sulfate (DSS) was used to establish the model for 24 h. The mice in the transplantation group were injected with 0.4 ml of 4 ', 6-diaminol-2-phenylindole (DAPI) -labeled P3-BM-MNCs cell suspension (3.2×10(6) cells/ml), and the mice in the model group and the normal control group were injected with 0.4 ml phosphate buffer (PBS).UC disease activity index (DAI) was used to test the general condition of mice; HE staining was used to observe the pathological changes of colon tissue; Real-time quantitative PCR was used to detect the expression of miRNA-21 and miRNA-155 mRNA. Results: DAI scores of normal control group, model group and transplantation group were 0 (0,1), 3.1 (2.8,3.3) and 2.7 (2.4,3.1),respectively. Compared with normal control group, the DAI score of model group and transplantation group was higher (P<0.05), and the DAI score of transplantation group was lower than that of model group (P<0.05). The gross scores of tissue injury in normal control group, model group and transplantation group were 0 (0, 1), 3 (3, 4) and 1 (1, 2), respectively,and the pathological scores of tissue injury were 0 (0, 1), 16 (12, 16) and 6 (6, 8), respectively,compared with the normal control group. The tissue injury score of the model group and the transplantation group was higher (P<0.05), and the tissue injury score of the transplantation group was lower than that of the model group (P<0.05). The expression levels of miRNA-21 mRNA in normal control group, model group and transplantation group were 0.87±0.15, 2.38±0.29 and 1.59±0.32, respectively, and the expression levels of miRNA-155 mRNA were 1.87±0.46, 7.38±1.97 and 3.92±0.84, respectively, compared with the normal control group, the expression of miRNA-21 and miRNA-155 mRNA in the model group and transplantation group was higher (P<0.01), the expression of miRNA-21 and miRNA-155 mRNA in the transplantation group was lower than that of the model group (P<0.05). Conclusion: Bone marrow mononuclear cell transplantation can improve the histopathological and DAI scores of mice with UC, which may be related to the down-regulation of miRNA-21 and miRNA-155 mRNA expression.
Collapse
Affiliation(s)
- S Yang
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - W Jiang
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - X Q Bao
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - W Yao
- School of Basic Medicine, Jiamusi University, Jiamusi 154002, China
| | - G Chen
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - H Zhang
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - X Chen
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - Q Bu
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - S H Yang
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| | - Y N Qi
- School of Clinical Medicine, Jiamusi University, Jiamusi 154002, China
| | - W Q Wang
- School of Basic Medicine, Jiamusi University, Jiamusi 154002, China
| | - Y P Han
- Department of Gastroenterology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154002, China
| |
Collapse
|
98
|
Zhu X, Ding Y, Yu Y, Wang M, Zhou W, Wang J, Zhu X, Zhang H, Wang M, Chai K, Zhang X, Luk A, Jiang W, Liu S, Zhang Q. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Cancer Chemother Pharmacol 2020; 87:349-359. [PMID: 33169186 DOI: 10.1007/s00280-020-04196-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 10/26/2020] [Indexed: 01/01/2023]
Abstract
PURPOSE This study evaluated the bioequivalence of China-manufactured biosimilar, HLX02, to reference China (CN)- and European Union (EU)-sourced trastuzumab. METHODS This was a two-part Phase 1 study conducted in healthy Chinese males. Part 1 evaluated the safety of different doses of HLX02 (2, 4, 6 or 8 mg/kg; intravenous infusion over 90 min, n = 3 per group). Part 2, a randomized, double-blind study, investigated the pharmacokinetics (PK), safety and immunogenicity of study drugs (HLX02 [n = 37], CN-trastuzumab [n = 35] or EU-trastuzumab [n = 37] at the dose suggested by Part 1 results). The primary PK endpoint was the area under the serum concentration-time curve from time 0 to infinity (AUCinf). Equivalence was concluded if the 90% confidence interval (CI) for the geometric least squares mean ratio (GLSMR) fell in the equivalence criteria of 0.80-1.25. RESULTS In Part 1, all doses of HLX02 were well tolerated and 6 mg/kg was suggested for Part 2. The GLSMRs and 90% CIs for AUCinf were: 0.950 (0.891-1.013), 0.914 (0.858-0.973) and 0.962 (0.902-1.025) for HLX02 versus CN-trastuzumab, HLX02 versus EU-trastuzumab and CN-trastuzumab versus EU-trastuzumab, respectively. Secondary endpoints comparisons also fell in the equivalence criteria. Treatment-emergent adverse events were reported in 75.7, 86.5 and 70.3% of the subjects in HLX02, CN-trastuzumab, and EU-trastuzumab groups, respectively. No serious adverse events or deaths occurred. No treatment-related anti-drug antibodies were detected. CONCLUSION This study demonstrated comparable safety profiles and PK bioequivalence among HLX02, CN-trastuzumab and EU-trastuzumab in healthy Chinese male subjects. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02581748, registered at October 19, 2015.
Collapse
Affiliation(s)
- X Zhu
- Phase 1 Clinical Trial Laboratory, The First Hospital of Jilin University, Changchun, China
| | - Y Ding
- Phase 1 Clinical Trial Laboratory, The First Hospital of Jilin University, Changchun, China
| | - Y Yu
- Phase 1 Clinical Trial Laboratory, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou, 215004, China
| | - M Wang
- Phase 1 Clinical Trial Laboratory, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou, 215004, China
| | - W Zhou
- Phase 1 Clinical Trial Laboratory, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou, 215004, China
| | - J Wang
- Internal Medicine Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - X Zhu
- Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - H Zhang
- Phase 1 Clinical Trial Laboratory, The First Hospital of Jilin University, Changchun, China
| | - M Wang
- Phase 1 Clinical Trial Laboratory, The First Hospital of Jilin University, Changchun, China
| | - K Chai
- Shanghai Henlius Biotech, Inc., Shanghai, China
| | - X Zhang
- Shanghai Henlius Biotech, Inc., Shanghai, China
| | - A Luk
- Shanghai Henlius Biotech, Inc., Shanghai, China
| | - W Jiang
- Shanghai Henlius Biotech, Inc., Shanghai, China
| | - S Liu
- Shanghai Henlius Biotech, Inc., Shanghai, China
| | - Q Zhang
- Phase 1 Clinical Trial Laboratory, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou, 215004, China.
| |
Collapse
|
99
|
Jiang W, Wang L, Zhang Y, Li H. Circ-ATP5H Induces Hepatitis B Virus Replication and Expression by Regulating miR-138-5p/ TNFAIP3 Axis. Cancer Manag Res 2020; 12:11031-11040. [PMID: 33173336 PMCID: PMC7648158 DOI: 10.2147/cmar.s272983] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 10/01/2020] [Indexed: 12/17/2022] Open
Abstract
Background Circular RNAs (circRNAs) play an important regulatory role in various cancers, including hepatocellular carcinoma (HCC). This study aimed to investigate the function of hsa_circ_0006942 (circ-ATP5H) in hepatitis B virus (HBV)-associated HCC and its underlying mechanism. Methods The levels of circ-ATP5H, miR-138-5p and tumor necrosis factor alpha-induced protein 3 (TNFAIP3) were determined using quantitative real-time polymerase chain reaction (qRT-PCR) or Western blot assay. The copies of HBV DNA were examined using qRT-PCR. The levels of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were detected via enzyme-linked immunosorbent assay (ELISA). Dual-luciferase reporter assay was used to analyze the interactions among circ-ATP5H, miR-138-5p and TNFAIP3. Results Circ-ATP5H and TNFAIP3 levels were increased, while miR-138-5p level was reduced in HBV-positive HCC tissues and cells. Knockdown of circ-ATP5H hindered HBV DNA replication and decreased HBsAg and HBeAg levels in HBV-infected cells. Circ-ATP5H silencing suppressed HBV replication and expression by regulating miR-138-5p. Moreover, miR-138-5p blocked HBV replication and expression via targeting TNFAIP3. Furthermore, circ-ATP5H up-regulated TNFAIP3 via absorbing miR-138-5p. Conclusion Circ-ATP5H promoted HBV replication and expression through modulating miR-138-5p/TNFAIP3 axis, suggesting a new biomarker for HBV-related HCC treatment.
Collapse
Affiliation(s)
- Wenxiu Jiang
- Department of Infectious Diseases, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang City, Jiangsu Province, People's Republic of China
| | - Lili Wang
- Department of Clinical Research, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing City, Jiangsu Province, People's Republic of China
| | - Yajuan Zhang
- Department of Infectious Diseases, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang City, Jiangsu Province, People's Republic of China
| | - Hongliang Li
- Department of Infectious Diseases, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang City, Jiangsu Province, People's Republic of China
| |
Collapse
|
100
|
Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, Cheng Y, Sun G, Deng Y, Zhong H, Li Y, Qian X, Zhang L, Zhang J, Chen K, Zhang L, Li W, Jiang W, Liu S, Chai K. 104P Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|